Accuray Partners with GE Healthcare to Advance Precision Radiation Therapy
Radiation therapy innovator, Accuray Incorporated (Nasdaq: ARAY), will collaborate with GE Healthcare to improve diagnosis and treatment across the spectrum of cancer care.
The partnership will bring together GE Healthcare’s precision diagnostic tools and Accuray’s innovative radiation therapy delivery capabilities, advancing the practice of radiation therapy and helping deliver personalized care to patients diagnosed with cancer.
- The collaboration will initially focus on the treatment of lung and brain cancers with an emphasis on early detection, functional diagnostics and targeted, precise treatment delivery.
- The partnership will allow Accuray to elevate the visibility of our solutions and ultimately, make potentially life-saving radiation therapy treatments available to more people.
- The agreement allows each party to continue to cooperate with other technologies.
Estimates show that more than one million U.S. cancer patients will receive treatment with radiation therapy in 2022.